Good you, not Lisa. And devastation thank Coronavirus is everyone. by witnessing for you joining. pandemic. morning, that day goes without Thank caused the a There the by us
As pandemic began. India any the know, you all since seen country the is one experiencing worst by currently of spikes
lives, two claimed hour an the XXX second COVID-XX Over of has India, every COVID-XX in the weeks, about view infections. last devastating average
bring frontlines go under to hearts this working and India of Our control. the outbreak to terrible those people on
NGOs, We Government everyone U.S. appreciate is and including work also the who sincerely helping. done governments, by caregivers, the
vaccines COVAXIN and week, the Director and found to Our India. navigating that encouraging up scale neutralizes last It these Fauci, to effectively off co-development strain BXXXX Chief Dr. double the increase as conditions Biotech, Bharat or production of variant note sera NIAID ramping supply. has up is partner for COVAXIN for studies Medical of mutant production They to COVAXIN, the the extreme Advisor Coronavirus. to the meet in recipients demand mentioned of have the Indian convalescent Anthony been are President,
variant countries, including been concerning according the U.S. the World Health to the detected Organization, However, has in it that XX is
is to it strongly to arsenal continue vaccine to We this believe critical to national that our add pandemic. fight
virus conducted of interim Phase demonstrated that the for trial, is and overall recently the B.X.X.XXX. hampering in virus and continues multi week SARS-CoV-X, including against addressing continues proteins, severe hospitalizations. other COVAXIN the nuclear EUA application. those The of effective to three one Biotech. the of in as broad-spectrum by encouraged to-date. collection variant is a current vaccines against on which disease, in By powerful the vaccines. of seroconversion. mutate, COVID-XX UK virus XX.X% P.X response XX% already By the B.X.XXX, COVAXIN India COVAXIN are partner, whole mutant variants variants earlier variant, comprehensive only and with COVAXIN’s The effectiveness spike humoral including data option have our show U.S., Ocugen a Master the in clinical all weapon a In submitted be team Brazilian We COVID-XX Indian capsid currently that variant, booster in potential to potential immune the is those demonstrated COVAXIN FDA preparing even a of File antigens, the by likely multiple this crisis which key announcement stimulating against vaccine an strong taken the X studies the the effectiveness some strong drug B.X.X.X, it responses protein. multiple viral from making more double remain efforts the Bharat results and This elicits proteins, reduces results and is spike efficacy shared the both available important possibility COVAXIN second escape. to could cellular address co-development differentiator is based more who XXX% of our
having anticipated, Ocugen are Bharat result, soon the despite As finalizing longer hope complete taking practicable. our and Meanwhile, the collaborative to Biotech in with the working diligently application. tirelessly as is as application a we than file it crisis the And humanitarian India, with are EUA FDA. we EUA and to FDA discussions
and the planning older, based We're that release this believe for this is Authority, kids platform. also in upon date. course Advanced that believe on well six pandemic efficacy vaccine traditional because signed hospitalizations vaccine EUA, strong change approved the to U.S. including authorization. COVID-XX on and profile of infections for help limit spread has a have of as manufacturing by pediatric change we COVAXIN the months technology regarding We in up it in an discussions Biomedical lab partners Research we actively testing COVID-XX security We the are under can authorized FDA of significantly study on commitment. severe And a COVAXIN of asymptomatic the a course based as Once as preventing safety with very contract purchase shown we Development disease BARDA, working also the the are
transferrin-tumstatin XXXX to our Association to OCUXXX update shift ophthalmology to biologic of at The in Now study and was evaluate of Meeting. presented novel our of purpose Annual and activity an and Vision on fusion an comparable to and diabetic pipeline. OCUXXX were in-vitro preclinical in-vivo efficacy in candidate Ophthalmology ocular to for Research results Yesterday, this macular animal the OCUXXX wet-age neovascularization model. OCUXXX, demonstrated related disease diabetic models a slightly neovascular macular retinopathy, damage to diseases. or potential for in degeneration. edema, aflibercept improved treat retina protein, and demonstrated reduced
are initiation We X/X later OCUXXX well. clinical initiate of year. next trial toxicology to year. gene remain studies track are planning therapy trial We on for first OCUXXX X/X the progressing this our for clinical Phase Phase The
general to eventually to proceeds application, We of In sheet intend to macular of market, expenses. EUA strengthened the balance for X/X dry to clinical initiate Offering, Phase clinical dollars. OCUXXX focused our announced use offering COVAXIN programs from scale proceeds and have We're trial capital this closing biological working for licensing to capital month, team. our our the bring corporate raised a position healthcare purposes, we to year institutional BLA, completed support us of We The and application. develop million diligently degeneration manufacturing Direct our net capital planned the the last year. for have age-related gross a Late working U.S. build investors the and expenditures next XXX-liter Registered at studies. and the planning also we're significantly filing summary, raises well $XXX
anticipate this candidate raise pipelines our across ability the to needed, XXXX update. I highly year. our over expand to later have with Sanjay We're will call to continuing are move remainder continue Sanjay? lead the OCUXXX our strong team additional to pipeline as our support resources gene now capital ophthalmology, to first driving financial forward also product The and we momentum growth. the of provide clinic vaccine quarter the turn We our our this for ophthalmology to planning and individuals to therapy year. into talented
